selegiline has been researched along with natriuretic peptide, c-type in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alamri, Y; Anderson, TJ; Dalrymple-Alford, JC; Espiner, EA; Prickett, TC | 1 |
1 other study(ies) available for selegiline and natriuretic peptide, c-type
| Article | Year |
|---|---|
C-type natriuretic peptide in Parkinson's disease: reduced secretion and response to deprenyl.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cognition Disorders; Female; Humans; Male; Middle Aged; Natriuretic Peptide, C-Type; Parkinson Disease; Retrospective Studies; Selegiline; Severity of Illness Index; Time Factors | 2014 |